1. Home
  2. PTHL vs SABS Comparison

PTHL vs SABS Comparison

Compare PTHL & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTHL
  • SABS
  • Stock Information
  • Founded
  • PTHL 1998
  • SABS 2014
  • Country
  • PTHL China
  • SABS United States
  • Employees
  • PTHL N/A
  • SABS N/A
  • Industry
  • PTHL
  • SABS Biotechnology: Pharmaceutical Preparations
  • Sector
  • PTHL
  • SABS Health Care
  • Exchange
  • PTHL Nasdaq
  • SABS Nasdaq
  • Market Cap
  • PTHL 13.5M
  • SABS 15.8M
  • IPO Year
  • PTHL 2024
  • SABS N/A
  • Fundamental
  • Price
  • PTHL $1.02
  • SABS $2.28
  • Analyst Decision
  • PTHL
  • SABS Strong Buy
  • Analyst Count
  • PTHL 0
  • SABS 5
  • Target Price
  • PTHL N/A
  • SABS $10.00
  • AVG Volume (30 Days)
  • PTHL 1.9M
  • SABS 85.9K
  • Earning Date
  • PTHL 01-01-0001
  • SABS 11-05-2025
  • Dividend Yield
  • PTHL N/A
  • SABS N/A
  • EPS Growth
  • PTHL N/A
  • SABS N/A
  • EPS
  • PTHL N/A
  • SABS N/A
  • Revenue
  • PTHL $448,196.00
  • SABS $114,698.00
  • Revenue This Year
  • PTHL N/A
  • SABS N/A
  • Revenue Next Year
  • PTHL N/A
  • SABS N/A
  • P/E Ratio
  • PTHL N/A
  • SABS N/A
  • Revenue Growth
  • PTHL N/A
  • SABS N/A
  • 52 Week Low
  • PTHL $0.51
  • SABS $1.00
  • 52 Week High
  • PTHL $32.00
  • SABS $6.60
  • Technical
  • Relative Strength Index (RSI)
  • PTHL 30.37
  • SABS 54.42
  • Support Level
  • PTHL $0.70
  • SABS $2.03
  • Resistance Level
  • PTHL $1.18
  • SABS $2.34
  • Average True Range (ATR)
  • PTHL 0.15
  • SABS 0.12
  • MACD
  • PTHL 0.68
  • SABS 0.02
  • Stochastic Oscillator
  • PTHL 76.30
  • SABS 84.00

About PTHL Pheton Holdings Ltd Class A Ordinary Shares

Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: